| HOME >> BIOLOGY >> TECHNOLOGY |
STAAR ALSO RECEIVES APPROVAL TO MARKET HYPEROPIC ICL
APPROVALS POSITION COMPANY FOR CONTINUED GROWTH IN KEY MARKET
MONROVIA, Calif., Feb. 29 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced it has received approval from the State Food and Drug Administration of the People's Republic of China (SFDA) to market the STAAR Visian(TM) Toric Implantable Collamer Lens to ophthalmologists and other eye care professionals in the country for the treatment of nearsightedness and astigmatism. In addition the SFDA granted approval to STAAR to market the STAAR Visian ICH, an implantable collamer lens to correct hyperopia or farsightedness.
"This approval has significant strategic importance for STAAR and positions us for continued growth in China," said Barry G. Caldwell, President and CEO of STAAR Surgical. "The approval of both the Visian Toric ICL and the Visian Hyperopic ICL represents a solid endorsement of the STAAR technology. The Visian Myopic ICL was approved in China during July 2006 and has enjoyed significant growth. With these additional approvals, we are positioned to expand our presence in a market where the demographics are very favorable."
According to Market Scope, a leading source for ophthalmic market data,
there are over 500 million myopes and nearly 50 million hyperopes in China
making it the largest potential refractive market in the world. In South
Korea, where the population is believed to have a mean myopia rate similar
to that of China, phakic implant procedures are estimated to have reached
seven percent of the LASIK market. According to data presented at an
ophthalmic
'/>"/>
| SOURCE STAAR Surgical Copyright©2008 PR Newswire. All rights reserved |